Promoting HPV Vaccination Among Young Adults in Texas

January 20, 2026 updated by: M.D. Anderson Cancer Center
This clinical trial studies how to improve the human papillomavirus (HPV) vaccination rate in young adults in Texas. This trial aims to learn more about how researchers and health care providers can increase HPV vaccination among college students.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the impact of addressing individual and system levels of influence on HPV vaccination initiation and completion rates.

II. To gain insight into mechanisms of the intervention's efficacy, individual differences, and implementation of the intervention using mixed methods.

OUTLINE: Participants are randomized to 1 of 6 groups.

GROUP I: Participants receive standard Centers for Disease Control and Prevention (CDC) information about HPV vaccination.

GROUP II: Participants receive video narratives about HPV vaccination.

GROUP III: Participants receive written narratives about HPV vaccination.

GROUP IV: Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.

GROUP V: Participants receive enhanced access to vaccination and video narratives about HPV vaccination.

GROUP VI: Participants receive enhanced access to vaccination and written narratives about HPV vaccination.

After completion of study, participants are followed up at 3 and 9 months.

Study Type

Interventional

Enrollment (Estimated)

1200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77030
        • M D Anderson Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 26 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up to 26 years of age and the fact that individuals 18 years and older can consent by themselves for on-site vaccination
  • Ability to read and understand English
  • Self-identification as not yet having received any HPV vaccine injections. Self-identification is justified because it is safe to be vaccinated again, which could happen if a previously vaccinated person forgets their vaccination. Furthermore, in a person previously vaccinated with an older version of the vaccine, which targeted fewer HPV types, receiving the newer version would be advantageous and not cause any harm. Alternatives to self-identification, such as obtaining medical records from doctors' offices, would be very challenging for young adults, especially for those who do not remember when and where they might have received vaccination
  • Access to a smart phone, tablet or computer that is connected to the internet
  • Current enrollment in one of the participating schools with an anticipated continuous enrollment of at least 9 months

Exclusion Criteria:

  • Being pregnant
  • Having a life-threatening allergy to any component of the HPV vaccine

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group I (standard CDC information)
Participants receive standard CDC information about HPV vaccination.
Other: Questionnaire Administration
Ancillary studies
Other: Interview
Ancillary studies
Other: Informational Intervention
Receive standard CDC information
Other: Informational Intervention
Receive video narratives
Other: Informational Intervention
Receive written narratives
Experimental: Group II (video narratives)
Participants receive video narratives about HPV vaccination.
Other: Questionnaire Administration
Ancillary studies
Other: Interview
Ancillary studies
Other: Informational Intervention
Receive standard CDC information
Other: Informational Intervention
Receive video narratives
Other: Informational Intervention
Receive written narratives
Experimental: Group III (written narratives)
Participants receive written narratives about HPV vaccination.
Other: Questionnaire Administration
Ancillary studies
Other: Interview
Ancillary studies
Other: Informational Intervention
Receive standard CDC information
Other: Informational Intervention
Receive video narratives
Other: Informational Intervention
Receive written narratives
Experimental: Group IV (enhanced access to vaccine, CDC information)
Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.
Other: Questionnaire Administration
Ancillary studies
Other: Interview
Ancillary studies
Other: Informational Intervention
Receive standard CDC information
Other: Informational Intervention
Receive video narratives
Other: Informational Intervention
Receive written narratives
Other: Enhancing Accessibility to Health Care
Receive enhanced access to vaccination
Experimental: Group V (enhanced access to vaccine, video narratives)
Participants receive enhanced access to vaccination and video narratives about HPV vaccination.
Other: Questionnaire Administration
Ancillary studies
Other: Interview
Ancillary studies
Other: Informational Intervention
Receive standard CDC information
Other: Informational Intervention
Receive video narratives
Other: Informational Intervention
Receive written narratives
Other: Enhancing Accessibility to Health Care
Receive enhanced access to vaccination
Experimental: Group VI (enhanced access to vaccine, written narratives)
Participants receive enhanced access to vaccination and written narratives about HPV vaccination.
Other: Questionnaire Administration
Ancillary studies
Other: Interview
Ancillary studies
Other: Informational Intervention
Receive standard CDC information
Other: Informational Intervention
Receive video narratives
Other: Informational Intervention
Receive written narratives
Other: Enhancing Accessibility to Health Care
Receive enhanced access to vaccination

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Rate of human papillomavirus (HPV) vaccination initiation
Time Frame: At 3 months
At 3 months
Rate of HPV vaccination completion
Time Frame: At 9 months
At 9 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

M.D. Anderson Cancer Center

Collaborators

National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Qian Lu, MD,PHD, M.D. Anderson Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 26, 2021

Primary Completion (Estimated)

July 31, 2026

Study Completion (Estimated)

July 31, 2026

Study Registration Dates

First Submitted

August 25, 2021

First Submitted That Met QC Criteria

September 15, 2021

First Posted (Actual)

September 27, 2021

Study Record Updates

Last Update Posted (Actual)

January 21, 2026

Last Update Submitted That Met QC Criteria

January 20, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-1142 (Other Identifier: M D Anderson Cancer Center)
  • NCI-2021-09416 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
  • R01CA248216 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Human Papillomavirus Infection

Clinical Trials on Questionnaire Administration

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe